Sugi Predict

Sugi Predict / Compounds / SCHEMBL30915565

SCHEMBL30915565

SCHEMBL30915565

CC(=O)NCCCC[C@H](NC(=O)[C@H](C)N)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 4/20 0.61
▸ NOD1 Q9Y239 3/20 0.50
▸ SIRT5 Q9NXA8 2/20 0.49
▸ GNPAT O15228 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ SIRT6 Q8N6T7 1/20 0.45
▸ SIRT1 Q96EB6 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ ALB P02768 2/20 0.43
▸ PAOX Q6QHF9 2/20 0.42
▸ ADRA1A P35348 1/20 0.41
▸ FNTA P49354 1/20 0.41
▸ FNTB P49356 1/20 0.41
▸ PGGT1B P53609 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29394341 0.88 FOLH1 (0.58) FOLH1NOD1SIRT5GNPATSMN1; SMN2
SCHEMBL14075788 0.88 FOLH1 (0.58) FOLH1NOD1SIRT5GNPATSMN1; SMN2
SCHEMBL16285430 0.88 SIRT5 (0.58) FOLH1NOD1SIRT5SIRT6SIRT1
SCHEMBL7225046 0.87 NOD1 (0.47) FOLH1NOD1SIRT5GNPATSMN1; SMN2
SCHEMBL7225059 0.87 NOD1 (0.47) FOLH1NOD1SIRT5GNPATSMN1; SMN2
SCHEMBL31099441 0.86 FOLH1 (0.56) FOLH1NOD1SIRT5GNPATSMN1; SMN2
SCHEMBL14942518 0.84 FOLH1 (0.64) FOLH1SIRT5GNPATSMN1; SMN2SIRT6
SCHEMBL25550095 0.84 FOLH1 (0.64) FOLH1SIRT5GNPATSMN1; SMN2SIRT6
SCHEMBL1200060 0.84 FOLH1 (0.71) FOLH1SIRT5GNPATSMN1; SMN2SIRT6
SCHEMBL2735591 0.84 FOLH1 (0.71) FOLH1SIRT5GNPATSMN1; SMN2SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027224-A1 ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2026-01-29 — — US claimed
EP-4674840-A1 CHEMICAL COUPLING LINKER AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2026-01-07 — — EP claimed
EP-4631952-A1 GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-10-15 — — EP claimed
EP-4603487-A1 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-08-20 — — EP claimed
EP-4603109-A1 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-08-20 — — EP claimed
WO-2024235130-A9 POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-26 — — WO claimed
CN-120202027-A Antibody drug conjugate, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2025-06-24 — — CN claimed
CN-120202203-A Heterocyclic compounds, their preparation and use 四川科伦博泰生物医药股份有限公司 2025-06-24 — — CN claimed
WO-2024235128-A9 ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-19 — — WO claimed
WO-2024235136-A9 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-19 — — WO claimed
WO-2024235130-A1 POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-11-21 — — WO claimed
WO-2024235135-A1 MACROCYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-11-21 — — WO claimed
WO-2024235131-A1 MACROCYCLIC DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-11-21 — — WO claimed
WO-2024114531-A9 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-10-03 — — WO claimed
WO-2024114318-A9 DRUG LINKER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-10-03 — — WO claimed
WO-2024149093-A1 GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF 四川科伦博泰生物医药股份有限公司 2024-07-18 — — WO claimed
WO-2024114531-A1 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 — — WO claimed
WO-2024114523-A1 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 — — WO claimed
WO-2024114318-A1 DRUG LINKER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 — — WO claimed
CN-118105508-A Medicinal linker compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-05-31 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027224-A1 ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF H1-3, H1-4, H1-2 FOLH1 488/4885NOD1 4690/4885SIRT5 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.